Invezz is an independent platform with the goal of helping users achieve financial freedom. In order to fund our work, we partner with advertisers who compensate us for users that Invezz refers to their services. While our reviews and assessments of each product on the site are independent and unbiased, brands may pay to appear higher up our table rankings or place ads in specific areas of the site. The order in which products and services appear on Invezz does not represent an endorsement from us, and please be aware that there may be other platforms available to you than the products and services that appear on our website. Read more about how we make money >
Galera Therapeutics, Inc. (NASDAQ:GRTX)
|Dividend Rate (ttm)||0.0000|
|Trading Day||Jan 25|
|Day's Range||2.55 - 2.77|
|52 Week Range||1.19 - 12.99|
Galera Therapeutics, Inc. earnings reports (2020)
|Q3 2020||Q2 2020||Q1 2020||Q1 2020|
|Number of Estimates||3||3||N.A||N.A|
|EPS Surprise Dollar||0.080667018890381||0.01||N.A||N.A|
|EPS Report Date||10-11-2020||10-08-2020||11-05-2020||11-05-2020|
|Fiscal End Date||30-09-2020||30-06-2020||30-03-2020||30-03-2020|
|Year Ago % Change||N.A||-66.67%||N.A||N.A|
Galera Therapeutics, Inc. earnings reports (2019)
|Q4 2019||Q3 2019||Q2 2019|
|Number of Estimates||N.A||N.A||N.A|
|EPS Surprise Dollar||N.A||N.A||N.A|
|EPS Report Date||10-03-2020||10-12-2019||27-08-2019|
|Fiscal End Date||31-12-2019||29-09-2019||29-06-2019|
|Year Ago % Change||N.A||N.A||N.A|
Galera Therapeutics, Inc. income statements (2020) (USD)
|June 2020||June 2020||March 2020||March 2020|
|Cost of Revenue||95K||95K||80K||80K|
|Research & Development||13.84M||13.84M||14.25M||14.25M|
|Selling General & Admin||3.78M||3.78M||3.49M||3.49M|
|Other Income Expense Net||-0.94M||-0.94M||-599K||-599K|
|Net Income Basic||-18.66M||-18.66M||-18.42M||-18.42M|
Galera Therapeutics, Inc. income statements (2019) (USD)
|December 2019||September 2019|
|Cost of Revenue||79K||75K|
|Research & Development||13.28M||11.04M|
|Selling General & Admin||2.81M||1.74M|
|Other Income Expense Net||-513K||-495K|
|Net Income Basic||-17.67M||-15.46M|
Galera Therapeutics, Inc. balance sheet (2020) (USD)
|June 2020||March 2020||March 2020|
|Other Current Assets||3.99M||4.50M||4.50M|
|Short Term Investments||88.53M||98.94M||98.94M|
|Long Term Investments||N.A||N.A||N.A|
|Tangible Assets (Net)||39.36M||49.04M||49.04M|
|Other Current Liabilities||5.37M||5.72M||5.72M|
|Total Current Liabilities||12.40M||12.65M||12.65M|
|Long Term Debt||61.29M||64.82M||64.82M|
|Current Long Term Debt||N.A||N.A||N.A|
Galera Therapeutics, Inc. balance sheet (2019) (USD)
|December 2019||September 2019|
|Other Current Assets||5.28M||4.20M|
|Short Term Investments||93.93M||52.23M|
|Long Term Investments||N.A||N.A|
|Tangible Assets (Net)||65.59M||26.58M|
|Other Current Liabilities||5.45M||3.57M|
|Total Current Liabilities||9.69M||9.08M|
|Long Term Debt||43.79M||42.92M|
|Current Long Term Debt||N.A||N.A|
Galera Therapeutics, Inc. cash flow (2020) (USD)
|June 2020||March 2020|
|Changes in Receivables||N.A||N.A|
|Changes in Inventories||N.A||N.A|
|Investing Activity (other)||N.A||N.A|
|Total Investing Cash Flows||9.67M||-4.4M|
|Other Financing Cash Flows||N.A||N.A|
|Cash Flow Financing||41K||20.01M|
|Exchange Rate Effect||N.A||N.A|
Galera Therapeutics, Inc. cash flow (2019) (USD)
|Changes in Receivables||N.A|
|Changes in Inventories||N.A|
|Investing Activity (other)||N.A|
|Total Investing Cash Flows||-41.79M|
|Other Financing Cash Flows||-20M|
|Cash Flow Financing||58.03M|
|Exchange Rate Effect||N.A|
Galera Therapeutics, Inc. dividends (USD)
Galera Therapeutics Inc has a market cap or net worth of $71.91 million. The enterprise value is $0.
Galera Therapeutics Inc has 26.44 million shares outstanding.
The trailing PE ratio is 0.0000 and the forward PE ratio is -1.2346. Galera Therapeutics Inc's PEG ratio is 0.0000.
Stock Price Statistics
The stock price has decreased by -0.4205%. The beta is 0.5074, so Galera Therapeutics Inc's price volatility has been lower than the market average.
In the last 12 months, Galera Therapeutics Inc had revenue of $0 and earned $0 in profits. Earnings per share was $.
Galera Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer.
Galera's lead product candidate is avasopasem manganese (GC4419, also referred to as avasopasem), a highly selective small molecule superoxide dismutase (SOD) mimetic initially being developed for the reduction of radiation-induced severe oral mucositis (SOM). Avasopasem is being studied in the Phase 3 ROMAN trial to assess its ability to reduce the incidence and severity of SOM induced by radiotherapy in patients with locally advanced head and neck cancer (HNC), its lead indication.
It is also being studied in the EUSOM Phase 2a multi-center trial in Europe assessing the safety of avasopasem in patients with HNC undergoing standard-of-care radiotherapy, the AESOP Phase 2a trial to assess its ability to reduce the incidence of esophagitis induced by radiotherapy in patients with lung cancer, and a Phase 2 trial in hospitalized patients who are critically ill with COVID-19. A pilot Phase 1/2 trial of avasopasem in combination with stereotactic body radiation therapy (SBRT) in patients with locally advanced pancreatic cancer (LAPC) has completed enrollment and reported interim results, with follow-up ongoing.
The FDA granted Fast Track and Breakthrough Therapy designations to avasopasem for the reduction of SOM induced by radiotherapy. Galera's second dismutase mimetic product candidate, GC4711, is being developed specifically to augment the anti-cancer efficacy of SBRT, and is currently being studied in the GRECO-1 Phase 1/2 trial in combination with SBRT in patients with non-small cell lung cancer.
Galera is headquartered in Malvern, PA..